Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

zilretta

  • Home
  •  
  • zilretta



  • Most Read
  • Latest Comments
  • Regeneus begins to etch pathway to drug commercialisation, exuding confidence in their tech
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Regeneus begins to etch pathway to drug commercialisation, exuding confidence in their tech
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Regeneus begins to etch pathway to drug commercialisation, exuding confidence in their tech
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Regeneus begins to etch pathway to drug commercialisation, exuding confidence in their tech
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Regeneus begins to etch pathway to drug commercialisation, exuding confidence in their tech
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • MVP eyes increased global distribution of Penthrox green whistle after raising $20m
    MVP eyes increased global distribution of Penthrox green whistle after raising $20m
    • News

  • Regeneus begins to etch pathway to drug commercialisation, exuding confidence in their tech
    Regeneus begins to etch pathway to drug commercialisation, exuding confidence in their tech
    • News

  • Wellfully set to jump into $9 billion market with FDA registration for their knee pain patch
    Wellfully set to jump into $9 billion market with FDA registration for their knee pain patch
    • News

  • Aussie opioid manufacturer cashed up following $33m sale of facility
    Aussie opioid manufacturer cashed up following $33m sale of facility
    • News

  • Could this pharma company hold the answer to overuse of opioids?
    Could this pharma company hold the answer to overuse of opioids?
    • News

  • Regeneus begins to etch pathway to drug commercialisation, exuding confidence in their tech
    • News

    Regeneus begins to etch pathway to drug commercialisation, exuding confidence in their tech

    Modern medicine is akin to magic, a notion exemplified when looking at the regenerative power of stem cells.  Whilst we’ve barely scraped the surface of what these powerful cells can do, regenerative medicine holds promise as a “magic fix” for many an ailment.  Clinical stage regenerative medicine company Regeneus (ASX: RGS) is working to develop

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.